Literature DB >> 25622919

Predominant Glandular Cholinergic Dysautonomia in Patients With Primary Sjögren's Syndrome.

Richard Imrich1, Ilias Alevizos, Lolita Bebris, David S Goldstein, Courtney S Holmes, Gabor G Illei, Nikolay P Nikolov.   

Abstract

OBJECTIVE: The autonomic nervous system (ANS) modulates exocrine gland function. Available data show poor correlation between the degree of function and destruction of the exocrine glands in primary Sjögren's syndrome (SS), suggesting that other mechanisms, such as autonomic dysfunction, may be important in these patients. The aim of this study was to perform a comprehensive analysis of sympathoneural and sympathetic cholinergic function in well-characterized patients with primary SS.
METHODS: Twenty-one patients with primary SS (mean ± SEM age 44.2 ± 2.8 years) and 13 healthy control subjects (mean ± SEM age 50.8 ± 1.9 years) were assessed during orthostasis and intravenous injection of edrophonium (10 mg). The postganglionic sympathetic cholinergic system was evaluated by assessing sweat production by means of the Quantitative Sudomotor Axon Reflex Test (QSART). Tests of gastric emptying were used to assess the gastrointestinal ANS in primary SS patients.
RESULTS: The velocity index and the acceleration index were significantly higher (P < 0.05) in patients with primary SS as compared to controls, both before and during the orthostatic and edrophonium tests. Findings of other hemodynamic and neurochemical parameters did not differ between primary SS patients and controls during the orthostasis and edrophonium test; however, the edrophonium-induced saliva increment was lower in primary SS patients (P = 0.002). Abnormally low sweat production was found in 4 primary SS patients but in none of the controls, as determined by the QSART. Gastric empting was delayed in 53% of primary SS patients.
CONCLUSION: We observed subtle differences in several ANS domains, including the gastrointestinal and sympathocholinergic systems, suggesting the presence of a complex ANS dysfunction in primary SS. The impact was greatest on the exocrine glands, with subtle differences in the cardiac parasympathetic function that were independent of glandular inflammation and atrophy, suggesting an alternative mechanism of disease pathogenesis in primary SS.
© 2015, American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25622919      PMCID: PMC4414824          DOI: 10.1002/art.39044

Source DB:  PubMed          Journal:  Arthritis Rheumatol        ISSN: 2326-5191            Impact factor:   10.995


  23 in total

Review 1.  Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group.

Authors:  C Vitali; S Bombardieri; R Jonsson; H M Moutsopoulos; E L Alexander; S E Carsons; T E Daniels; P C Fox; R I Fox; S S Kassan; S R Pillemer; N Talal; M H Weisman
Journal:  Ann Rheum Dis       Date:  2002-06       Impact factor: 19.103

2.  Autonomic cardiovascular neuropathy in Sjögren's syndrome. A controlled study.

Authors:  A P Andonopoulos; J Christodoulou; C Ballas; A Bounas; D Alexopoulos
Journal:  J Rheumatol       Date:  1998-12       Impact factor: 4.666

3.  Anti-M(3) muscarinic cholinergic autoantibodies from patients with primary Sjögren's syndrome trigger production of matrix metalloproteinase-3 (MMP-3) and prostaglandin E(2) (PGE(2)) from the submandibular glands.

Authors:  Silvia Reina; Leonor Sterin-Borda; Daniela Passafaro; Enri Borda
Journal:  Arch Oral Biol       Date:  2011-03-03       Impact factor: 2.633

4.  Primary Sjogrens syndrome is associated with impaired autonomic response to orthostasis and sympathetic failure.

Authors:  W-F Ng; A J Stangroom; A Davidson; K Wilton; S Mitchell; J L Newton
Journal:  QJM       Date:  2012-09-13

5.  Hemodynamic effects of edrophonium chloride (Tensilon) infusion.

Authors:  J A Cooper; F Baratta; J Frieden; J Grossman
Journal:  Chest       Date:  1975-02       Impact factor: 9.410

6.  Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS).

Authors:  Xavier Mariette; Philippe Ravaud; Serge Steinfeld; Gabriel Baron; Joelle Goetz; Eric Hachulla; Bernard Combe; Xavier Puéchal; Yvon Pennec; Bernard Sauvezie; Aleth Perdriger; Gilles Hayem; Anne Janin; Jean Sibilia
Journal:  Arthritis Rheum       Date:  2004-04

7.  Etanercept in Sjögren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial.

Authors:  Vidya Sankar; Michael T Brennan; Marc R Kok; Rose Anne Leakan; Janine A Smith; Joan Manny; Bruce J Baum; Stanley R Pillemer
Journal:  Arthritis Rheum       Date:  2004-07

8.  Improved assay for plasma dihydroxyphenylacetic acid and other catechols using high-performance liquid chromatography with electrochemical detection.

Authors:  C Holmes; G Eisenhofer; D S Goldstein
Journal:  J Chromatogr B Biomed Appl       Date:  1994-03-04

Review 9.  Dysautonomia in Parkinson's disease: neurocardiological abnormalities.

Authors:  David S Goldstein
Journal:  Lancet Neurol       Date:  2003-11       Impact factor: 44.182

10.  Autoimmune autonomic ganglionopathy: treatment by plasma exchanges and rituximab.

Authors:  Richard Imrich; Steven Vernino; Basil A Eldadah; Courtney Holmes; David S Goldstein
Journal:  Clin Auton Res       Date:  2009-04-28       Impact factor: 4.435

View more
  8 in total

Review 1.  Autoimmune autonomic neuropathies and ganglionopathies: epidemiology, pathophysiology, and therapeutic advances.

Authors:  Elisabeth P Golden; Steven Vernino
Journal:  Clin Auton Res       Date:  2019-05-15       Impact factor: 4.435

2.  Cardiac autonomic function in patients with early multiple sclerosis.

Authors:  Richard Imrich; Miroslav Vlcek; Adela Penesova; Zofia Radikova; Andrea Havranova; Monika Sivakova; Pavel Siarnik; Branislav Kollar; Tomas Sokolov; Peter Turcani; Eva Heckova; Gilbert Hangel; Bernhard Strasser; Wolfgang Bogner
Journal:  Clin Auton Res       Date:  2021-03-04       Impact factor: 4.435

3.  Aspirin Triggered Resolvin D1 reduces inflammation and restores saliva secretion in a Sjögren's syndrome mouse model.

Authors:  Spencer Dean; Ching-Shuen Wang; Kihoon Nam; Christina L Maruyama; Bryan G Trump; Olga J Baker
Journal:  Rheumatology (Oxford)       Date:  2019-07-01       Impact factor: 7.580

4.  Association of calreticulin expression with disease activity and organ damage in systemic lupus erythematosus patients.

Authors:  Yichao Wang; Jiaogui Xie; Zhili Liu; Hongwei Fu; Qianyu Huo; Yajun Gu; Yunde Liu
Journal:  Exp Ther Med       Date:  2017-03-20       Impact factor: 2.447

5.  Autonomic dysfunction in primary Sjogren's syndrome: a prospective cohort analysis of 154 Korean patients.

Authors:  Jung Hee Koh; Seung-Ki Kwok; Jennifer Lee; Sung-Hwan Park
Journal:  Korean J Intern Med       Date:  2016-03-25       Impact factor: 2.884

6.  Salivary Gland Stem Cells Age Prematurely in Primary Sjögren's Syndrome.

Authors:  Sarah Pringle; Xiaoyan Wang; Gwenny M P J Verstappen; Janneke H Terpstra; Clarence K Zhang; Aiqing He; Vishal Patel; Rhiannon E Jones; Duncan M Baird; Fred K L Spijkervet; Arjan Vissink; Hendrika Bootsma; Robert P Coppes; Frans G M Kroese
Journal:  Arthritis Rheumatol       Date:  2019-01       Impact factor: 10.995

Review 7.  Cholinergic anti-inflammatory pathway and connective tissue diseases.

Authors:  Khalil Hajiasgharzadeh; Alireza Khabbazi; Ahad Mokhtarzadeh; Amir Baghbanzadeh; Zahra Asadzadeh; Elham Adlravan; Behzad Baradaran
Journal:  Inflammopharmacology       Date:  2021-06-14       Impact factor: 4.473

Review 8.  Autonomic Nervous System Dysfunction in Primary Sjögren's Syndrome.

Authors:  Kristen Davies; Wan-Fai Ng
Journal:  Front Immunol       Date:  2021-07-26       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.